Valeant Pharmaceuticals (VRX -1.4%) receives U.S. antitrust approval for its $24/share...

|About: Valeant Pharmaceuticals I... (VRX)|By:, SA News Editor

Valeant Pharmaceuticals (VRX -1.4%) receives U.S. antitrust approval for its $24/share acquisition of Obagi Medical (OMPI). The deal now needs the authorization of the Antimonopoly Committee of Ukraine. (PR)